Though clinical research will be needed to substantiate the utility of immunotherapy in treating NPM1-mutant AML, in vitro models, and a mice model, have shown that CAR-T cell therapies may have anti-leukemic utility while mitigating off-tumor toxicity [68]. The gene discussed is NPM1; the disease is acute myeloid leukemia.